Avanir Pharmaceuticals Invites Investors to JP Morgan Healthcare Conference Webcast

SAN DIEGO--(BUSINESS WIRE)--Jan. 6, 2005--AVANIR Pharmaceuticals (AMEX:AVN) will be presenting at the JP Morgan 23rd Annual Healthcare Conference being held next week in San Francisco, California. President and Chief Executive Officer Dr. Gerald J. Yakatan will present a corporate overview at 10:00 am Pacific Time, on Thursday, January 13, 2005.

The live webcast of the presentation will be accessible through AVANIR's website at http://www.avanir.com. To access the webcast, log on to AVANIR's site ten minutes prior to the presentation to register and download any necessary audio software. An archived version of the presentation will be available until March 13, 2005.

AVANIR Pharmaceuticals is a drug discovery and development company focused on treatments for chronic diseases. Our product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation, and infectious disease. The Company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.

The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect". The Company disclaims any intent or obligation to update these forward-looking statements. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.

    CONTACT: AVANIR Pharmaceuticals
             Patrice Saxon, 858-622-5202 (Investor Relations)

    SOURCE: AVANIR Pharmaceuticals